Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 7,594 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Bones Clear all

Conditions: Leukemia, Inborn Errors of Metabolism, Bone Marrow Failure Syndromes, Immunodeficiencies, Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome
Interventions: Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs); Biological
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 30 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis
Interventions: Sotatercept, Ruxolitinib; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Severe Aplastic Anemia
Interventions: cyclosporine, Matched Unrelated Donor Hematopoetic Stem Cell Transplant, horse anti-thymocyte globulin (ATG), rabbit anti-thymocyte globulin (ATG), Methotrexate, Fludarabine, Cyclophosphamide, low-dose total body irradiation (TBI), Immunosuppressive Therapy (IST); Drug · Procedure · Radiation
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 0 Years to 25 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 50
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more

Conditions: Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm
Interventions: Computed Tomography, Image Guided Radiation Therapy, Positron Emission Tomography, Questionnaire Administration; Procedure · Radiation · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Bone Cancer
Interventions: OST31-164; Drug
Lead sponsor: Emerald Clinical Inc.; Industry
Eligibility: 12 Years to 39 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 21
States / cities: Los Angeles, California • Orange, California • San Diego, California + 18 more

Conditions: Distal Radius Fracture
Interventions: Group 1 Elbow Flexed at 90 Degrees, Group 2 Elbow Fully Flexed; Other
Lead sponsor: Indiana Hand to Shoulder Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Childhood Acute Lymphoblastic Leukemia, Secondary Myelodysplastic Syndromes
Interventions: allogeneic bone marrow transplantation, laboratory biomarker analysis, filgrastim; Procedure · Other · Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 21
States / cities: Arcadia, California • San Francisco, California • Aurora, Colorado + 17 more

Conditions: Pain, Postoperative, Femur Fracture
Interventions: Ropivacaine, Epinephrine, Morphine, 0.9% sodium chloride solution; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Leukemia, Myelodysplastic Syndrome
Interventions: WT1-sensitized T cells; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Hip Fractures
Interventions: Exparel, Sodium Chloride; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 55 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Lexington, Kentucky • Worcester, Massachusetts

Conditions: Rhabdomyosarcoma, Ewing Sarcoma, Neuroblastoma, Wilms Tumor
Interventions: Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells; Biological
Lead sponsor: Children's National Research Institute; Other
Eligibility: 1 Year to 23 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2044
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Rib Fractures, Rib Fracture Multiple
Interventions: Bupivacaine, Fentanyl, morphine, hydromorphone, hydrocodone, acetaminophen, ketorolac, gabapentin, ketamine, ibuprofen; Drug
Lead sponsor: Andrew A Herring; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Oakland, California

Conditions: Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma
Interventions: Dinutuximab, Laboratory Biomarker Analysis, Pharmacological Study, Sargramostim; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 29 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 111
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 91 more

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Interventions: H3B-8800 (RVT-2001); Drug
Lead sponsor: Hemavant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 15
States / cities: Tucson, Arizona • Duarte, California • Irvine, California + 10 more

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Philadelphia Chromosome Negative Chronic Myelogenous Leukemia, Polycythemia Vera, Primary Myelofibrosis, Relapsing Chronic Myelogenous Leukemia
Interventions: fludarabine phosphate, triapine, laboratory biomarker analysis; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Neoplasms
Interventions: Doxorubicin, Trastuzumab, Cyclophosphamide, Paclitaxel, Epirubicin, Docetaxel, Carboplatin, Fluorouracil; Drug · Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Myelodysplastic Syndromes
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Day to 120 Years
Enrollment: 1,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2042
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myelodysplastic Syndromes
Interventions: Dasatinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Leukemia, Fungal Infection
Interventions: Posaconazole; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteopetrosis
Interventions: Interferon gamma-1b; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 1 Year and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Torrance, California • Minneapolis, Minnesota

Conditions: Cervical Cancer
Interventions: M7824, Carboplatin, Paclitaxel, Bevacizumab, Cisplatin, Radiotherapy; Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Stanford, California • Augusta, Georgia • Henderson, Nevada + 2 more

Conditions: GVHD, Bone Marrow Transplant Complications
Interventions: App-based Educational Intervention; Behavioral
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: San Diego, California

Conditions: Ankylosing Spondylitis
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 14
States / cities: Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 10 more

Conditions: Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: questionnaire administration, cryosurgery, pain therapy, quality-of-life assessment; Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 10
States / cities: Jacksonville, Florida • Ann Arbor, Michigan • Detroit, Michigan + 6 more

Search by objective public record fields.

Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases

Osteosarcoma Maintenance Therapy With OST31-164

Novel Exercises to Facilitate Recovery of Supination and Pronation for Distal Radius Fractures Managed With a Volar Plate

Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases

Efficacy of Peri-Incisional Multimodal Drug Injection Following Operative Management of Femur Fractures

Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation

Randomized Controlled Trial for Exparel Hip Fracture

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

US-guided SAPB for Rib Fractures in the ED

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia

ACTIMMUNE in Intermediate Osteopetrosis

Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases